Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retil Vein Occlusion - Overview
Retil Vein Occlusion - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Retil Vein Occlusion - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retil Vein Occlusion - Companies Involved in Therapeutics Development
3SBio Inc
Addmedica SAS
Annexin Pharmaceuticals AB
Calpain Therapeutics Pty Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Drive Therapeutics LLC
EyePoint Pharmaceuticals Inc
Gene Sigl Intertiol SA
Graybug Vision Inc
Kodiak Sciences Inc
Kuur Therapeutics Ltd
Lupin Ltd
Novartis AG
Ocular Therapeutix Inc
Outlook Therapeutics Inc
Panoptes Pharma GesmbH
Regeneron Pharmaceuticals Inc
Ripple therapeutics Corp
Retil Vein Occlusion - Drug Profiles
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aganirsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANXV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
axitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevacizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brolucizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
conbercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-28P001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxyurea - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KSI-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LKA-651 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit VEGF for Ophthalmology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Inhibit VEGF for Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CAPN1 and CAPN2 for Ischaemic Retil Vein Occlusion - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sunitinib malate CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vorolanib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Retil Vein Occlusion - Dormant Projects
Retil Vein Occlusion - Discontinued Products
Retil Vein Occlusion - Product Development Milestones
Featured News & Press Releases
Feb 08, 2020: Kodiak Sciences announces additiol safety, efficacy and durability data from ongoing phase 1b study of KSI-301 in patients with wet age-related macular degeneration, diabetic macular edema and retil vein occlusion at the angiogenesis, exudation, and degeneration 2020 meeting
Feb 05, 2020: Kodiak Sciences announces upcoming presentation of additiol KSI-301 phase 1b clinical study data at Angiogenesis, Exudation, and Degeneration 2020 meeting
Oct 11, 2019: Kodiak Sciences announces safety, efficacy and durability data from ongoing phase 1b study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retil Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Reti Subspecialty Day
Oct 07, 2019: Kodiak Sciences announces upcoming presentation of durability data from clinical development program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting
Oct 02, 2019: Graybug Vision initiates Phase 2b (ALTISSIMO) clinical trial of GB-102 in patients with Wet Age-Related Macular Degeneration
Sep 18, 2019: Graybug Vision initiates clinical trial in macular edema secondary to diabetic macular edema or retil vein occlusion
Sep 04, 2019: Kodiak Sciences announces upcoming presentations at EURETI Meeting
Jul 29, 2019: Kodiak’s anti-VEGF antibody yields positive data in Phase Ib study
Jul 24, 2019: Kodiak Sciences announces upcoming presentation at American Society of Reti Specialists (ASRS) 2019 Annual Meeting
Apr 24, 2019: Interface Biologics to present local drug delivery technology update at Bloom Burton & Co. Healthcare Investor Conference
Feb 08, 2019: Kodiak Sciences announces upcoming presentation of KSI-301 12-week phase 1a study data at Angiogenesis, Exudation, and Degeneration 2019 Meeting
Dec 21, 2018: Kodiak Sciences announces completion of 12-week phase 1a study of KSI-301 in patients with diabetic macular edema demonstrating safety and durability of responses following single dose of intravitreal anti-VEGFantibody biopolymer conjugate
Feb 14, 2012: Gene Sigl And Collaborators Demonstrate Successful Activity Of Topical Aganirsen In Models Of Retil Neovascular Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Retinal Vein Occlusion, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Retinal Vein Occlusion, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Retinal Vein Occlusion - Pipeline by 3SBio Inc, H1 2020
Retinal Vein Occlusion - Pipeline by Addmedica SAS, H1 2020
Retinal Vein Occlusion - Pipeline by Annexin Pharmaceuticals AB, H1 2020
Retinal Vein Occlusion - Pipeline by Calpain Therapeutics Pty Ltd, H1 2020
Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2020
Retinal Vein Occlusion - Pipeline by Drive Therapeutics LLC, H1 2020
Retinal Vein Occlusion - Pipeline by EyePoint Pharmaceuticals Inc, H1 2020
Retinal Vein Occlusion - Pipeline by Gene Signal International SA, H1 2020
Retinal Vein Occlusion - Pipeline by Graybug Vision Inc, H1 2020
Retinal Vein Occlusion - Pipeline by Kodiak Sciences Inc, H1 2020
Retinal Vein Occlusion - Pipeline by Kuur Therapeutics Ltd, H1 2020
Retinal Vein Occlusion - Pipeline by Lupin Ltd, H1 2020
Retinal Vein Occlusion - Pipeline by Novartis AG, H1 2020
Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H1 2020
Retinal Vein Occlusion - Pipeline by Outlook Therapeutics Inc, H1 2020
Retinal Vein Occlusion - Pipeline by Panoptes Pharma GesmbH, H1 2020
Retinal Vein Occlusion - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Retinal Vein Occlusion - Pipeline by Ripple therapeutics Corp, H1 2020
Retinal Vein Occlusion - Dormant Projects, H1 2020
Retinal Vein Occlusion - Discontinued Products, H1 2020